Dow Falls 150 Points; Oracle Posts Downbeat Results
Dow Falls 150 Points; Oracle Posts Downbeat Results
In trading on Tuesday, utilities shares fell by 1.1%.U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday.
美國股票今晨行情不一，道瓊斯指數週二下跌約150點。
Following the market opening Tuesday, the Dow traded down 0.36% to 44,242.81 while the NASDAQ rose 0.43% to 19,820.91. The S&P 500 also fell, dropping, 0.01% to 6,052.43.
週二市場開盤後，道瓊斯下跌0.36%，至44,242.81，而納斯達克上漲0.43%，至19,820.91。S&P 500也下跌，跌幅爲0.01%，至6,052.43。
Leading and Lagging Sectors
Communication services shares jumped by 2.3% on Tuesday.
領先和滯後板塊
週二，通信服務類股票上漲2.3%。
In trading on Tuesday, utilities shares fell by 1.1%.
週二，公用事業類股票下跌1.1%。
Top Headline
主要頭條
Oracle Corporation (NYSE:ORCL) posted weaker-than-expected earnings and sales results for its second quarter on Monday.
甲骨文公司（紐交所：ORCL）在週一發佈的第二季度業績中，業績和銷售結果低於預期。
The company reported second-quarter revenue of $14.06 billion, up 9% year-over-year. The revenue total missed a Street consensus estimate of $14.11 billion.
該公司報告第二季度營業收入爲140.6億美金，同比增長9%。營業收入總額未達到華爾街分析師的共識預期141.1億美金。
Equities Trading UP
股票交易上漲
- Chimerix, Inc. (NASDAQ:CMRX) shares shot up 172% to $2.36 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.
- Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) got a boost, surging 112% to $2.6400 after the company announced the FDA has approved its supplemental new drug application for acetadote.
- uniQure N.V. (NASDAQ:QURE) shares were also up, gaining 104% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.
- Chimerix, Inc. (納斯達克:CMRX) 的股票上漲了172%，達到$2.36，因該公司宣佈將向FDA提交dordaviprone的加速批准申請，用於治療複發性H3 K2700萬.mutant瀰漫性膠質瘤的患者。
- Cumberland Pharmaceuticals Inc. (納斯達克:CPIX) 的股票上漲了112%，達$2.6400，因該公司宣佈FDA已批准其對於acetadote的補充新藥申請。
- uniQure N.V. (納斯達克:QURE) 的股票也上漲，增加了104%，達到$15.00，因爲該公司宣佈與FDA就AMt-130的加速通道的關鍵要素達成協議。
Equities Trading DOWN
股票交易下跌
- CervoMed Inc. (NASDAQ:CRVO) shares dropped 75% to $2.54 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.
- Shares of Biora Therapeutics, Inc. (NASDAQ:BIOR) were down 44% to $0.7499.
- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) was down, falling 41% to $1.65. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.
- CervoMed Inc. (納斯達克:CRVO) 的股票下跌了75%，至$2.54，因爲該公司宣佈其Phase 20億試驗的Neflamapimod未能達到治療癡呆症的關鍵終點。
- Biora Therapeutics, Inc. (納斯達克:BIOR) 的股票下跌了44%，至$0.7499。
- MEDIROm Healthcare Technologies Inc. (納斯達克:MRM) 的股票下跌了41%，至$1.65。MEDIROm Healthcare以每ADS$1.75的價格定價其500萬的286萬美國存托股份的公開發行。
Commodities
In commodity news, oil traded up 0.1% to $68.40 while gold traded up 1% at $2,712.20.
商品
在商品資訊中，油價上漲0.1%，至68.40美元，而黃金上漲1%，至2712.20美元。
Silver traded up 0.4% to $32.750 on Tuesday, while copper fell 0.6% to $4.2500.
週二，白銀上漲0.4%，至32.750美元，銅下跌0.6%，至4.2500美元。
Euro zone
歐元區：
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.6%.
今天歐洲股市大部分下跌。歐元區的STOXX 600指數下跌0.2%，德國的DAX指數上漲0.2%，法國的CAC 40指數下跌0.6%。西班牙的IBEX 35指數下跌0.1%，而倫敦的FTSE 100指數下跌0.6%。
Asia Pacific Markets
亞太市場
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
週一，亞洲市場收盤漲跌互現，日本的日經225指數上漲0.18%，香港恒生指數上漲2.76%，中國的上海綜合指數下跌0.05%，印度的北交所指數下跌0.25%。
Economics
經濟學
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.
美國非農商業部門的勞動生產率在第三季度增長了2.2%，與初步讀數一致。
Now Read This:
現在閱讀這個：
- Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
- 亞馬遜將在15%左右振盪嗎？以下是週二的10個頂級分析師預測
譯文內容由第三人軟體翻譯。
